A Phase 3 interventional study of Fluvoxamine in Obsessive-Compulsive Disorder, Anxiety Disorders and Generalized Anxiety Disorder, sponsored by National Institute of Mental Health (NIMH). Completed. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2007-06-14.
Sponsored by National Institute of Mental Health (NIMH) · Phase 3, Interventional, and Treatment
Among 16 studies in Obsessive-Compulsive Disorder by National Institute of Mental Health (NIMH) — 2 open to participants now, 2 under way, none of them phase 3. Obsessive-Compulsive Disorder · National Institute of Mental Health (NIMH).
Among the 16 studies in Obsessive-Compulsive Disorder by National Institute of Mental Health (NIMH), this one is one of 2 that started in 1996, is one of 3 in phase 3, and was the 1st registered.
635 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →2 of the 16 studies in Obsessive-Compulsive Disorder by National Institute of Mental Health (NIMH) are open now, in 1 country. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
National Institute of Mental Health (NIMH) · Sites in United States
By country, each count listing its studies:
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 31 (26%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 1996.
Median enrollment 63 across the 4 interventional studies, 111 across the 10 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Mental Health (NIMH) is the lead sponsor of 367 studies on the registry; 45 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Obsessive-Compulsive Disorder by National Institute of Mental Health (NIMH), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if it is effective to treat children with anxiety disorders with fluvoxamine.
Fluvoxamine has been successfully used to treat obsessive-compulsive disorder (OCD) in adults and children. Anxiety disorders other than OCD, such as generalized anxiety disorder, social phobia, or separation anxiety, are very common in youth and are not always responsive to behavioral therapies alone. These disorders may respond to fluvoxamine.
A child will be evaluated for 3 weeks before he/she is assigned randomly (like tossing a coin) to receive either fluvoxamine or an inactive placebo for 8 weeks. After this double-blind phase (neither the child/parents nor the doctor know which treatment is being given), the child will have the option of continuing treatment during a 4-month open-label extension period (both the child/parents and the doctor know which the child is receiving).
A child may be eligible for this study if he/she:
Is 6 to 17 years old and has been diagnosed with an anxiety disorder (i.e., generalized anxiety disorder, social phobia, or separation anxiety).
To evaluate fluvoxamine in the treatment of children and adolescents with anxiety disorders.
Fluvoxamine is a serotonin reuptake inhibitor that is FDA-approved for the treatment of obsessive-compulsive disorder (OCD) in adults and children. Anxiety disorders other than OCD are very common in youth and are not always responsive to psychosocial therapies. Fluvoxamine is an alternative treatment.
After a 3-week period of evaluation, patients meeting study entry criteria are randomized to receive either fluvoxamine or placebo for 8 weeks. After this double-blind phase, patients can enter a 4-month open-label extension.
No study locations are listed for this record.
The record gives a start of Oct 1996 and a completion of Nov 1999. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluvoxamine
Obsessive-Compulsive Disorder →
National Institute of Mental Health (NIMH) →